- Home
- MLNK vs NTLA Comparison
MLNK vs NTLA Comparison
Compare MLNK & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- NTLA
- Stock Information
- Founded
- MLNK 1998
- NTLA 2014
- Country
- MLNK United States
- NTLA United States
- Employees
- MLNK N/A
- NTLA N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MLNK Technology
- NTLA Health Care
- Exchange
- MLNK Nasdaq
- NTLA Nasdaq
- Market Cap
- MLNK 1.7B
- NTLA 2.1B
- IPO Year
- MLNK 2021
- NTLA 2016
- Fundamental
- Price
- MLNK $20.62
- NTLA $17.99
- Analyst Decision
- MLNK Hold
- NTLA Buy
- Analyst Count
- MLNK 6
- NTLA 15
- Target Price
- MLNK $20.60
- NTLA $60.29
- AVG Volume (30 Days)
- MLNK 451.8K
- NTLA 1.6M
- Earning Date
- MLNK 10-30-2024
- NTLA 11-07-2024
- Dividend Yield
- MLNK N/A
- NTLA N/A
- EPS Growth
- MLNK N/A
- NTLA N/A
- EPS
- MLNK N/A
- NTLA N/A
- Revenue
- MLNK $307,559,000.00
- NTLA $45,967,000.00
- Revenue This Year
- MLNK $6.13
- NTLA $51.43
- Revenue Next Year
- MLNK $7.71
- NTLA $11.32
- P/E Ratio
- MLNK N/A
- NTLA N/A
- Revenue Growth
- MLNK 4.31
- NTLA N/A
- 52 Week Low
- MLNK $14.89
- NTLA $17.43
- 52 Week High
- MLNK $25.88
- NTLA $34.87
- Technical
- Relative Strength Index (RSI)
- MLNK 36.19
- NTLA 31.61
- Support Level
- MLNK $19.72
- NTLA $20.23
- Resistance Level
- MLNK $23.41
- NTLA $21.42
- Average True Range (ATR)
- MLNK 0.74
- NTLA 0.98
- MACD
- MLNK -0.37
- NTLA -0.34
- Stochastic Oscillator
- MLNK 16.04
- NTLA 8.85
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.